drugset
Drugs / Nicotinamide Adenine Dinucleotide
last change 10 days ago re-read 9 days ago

Nicotinamide Adenine Dinucleotide

also known as Coenzyme I for Injection · NAD+
Developed for
autoimmune thrombocytopenia
Investigated by
Beijing Children's Hospital · Institute of Hematology & Blood Diseases Hospital, China

Trials 2

today NCT07839130 · Ph 2 NCT06776510 · Ph 1/2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06776510 Jan → Dec 2025 overdue autoimmune thrombocytopenia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07839130 Oct 2026 → Apr 2028 expected — Beijing Children's Hospital Not yet recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as nicotinamide adenine dinucleotide “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗
1

NCT07839130 ↗
Known as Coenzyme I for Injection “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗
Known as NAD+ “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗
Route Intravenous “Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration” NCT06776510 ↗